Actinium Pharmaceuticals, Inc.ATNMNYSE
Loading
Year-over-year net income growth rate
Percentile
P85
Within normal range
vs 2Y Ago
2x
Strong expansion
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 25.40% |
| Q2 2025 | 56.85% |
| Q1 2025 | -139.60% |
| Q4 2024 | 42.50% |
| Q3 2024 | -1.89% |
| Q2 2024 | -30.95% |
| Q1 2024 | 7.01% |
| Q4 2023 | 29.77% |
| Q3 2023 | 12.55% |
| Q2 2023 | -37.55% |
| Q1 2023 | -3.66% |
| Q4 2022 | -12.38% |
| Q3 2022 | -21.98% |
| Q2 2022 | -51.43% |
| Q1 2022 | 35.97% |
| Q4 2021 | -24.71% |
| Q3 2021 | -27.92% |
| Q2 2021 | 5.62% |
| Q1 2021 | 16.61% |
| Q4 2020 | -15.16% |
| Q3 2020 | -19.78% |
| Q2 2020 | 18.43% |
| Q1 2020 | -23.20% |
| Q4 2019 | 30.26% |
| Q3 2019 | -31.27% |
| Q2 2019 | 11.34% |
| Q1 2019 | 10.28% |
| Q4 2018 | -2.80% |
| Q3 2018 | -26.42% |
| Q2 2018 | 22.98% |
| Q1 2018 | -22.29% |
| Q4 2017 | 18.35% |
| Q3 2017 | 10.36% |
| Q2 2017 | 12.50% |
| Q1 2017 | -20.40% |
| Q4 2016 | -1.47% |
| Q3 2016 | 0.38% |
| Q2 2016 | -50.44% |
| Q1 2016 | 32.69% |
| Q4 2015 | -65.76% |